Product Details
| Product Name:
(±)-Amiflamine |
CAS No.:
77502-96-6 |
| Purity:
≥98% |
Supply Ability:
10g |
| Release date:
2024/11/19 |
Product Introduction
Bioactivity
| Name | (±)-Amiflamine |
| Description | (±)-Amiflamine (2-dimethylphenethylamine) is an inhibitor of reversible MAO-A. |
| In vitro | The ex vivo approach was found to be valid for moclobemide in brain and liver and for cimoxatone in brain tissue;a slight underestimation of the MAO A inhibitory effect of the latter in the liver is likely.Definite underestimation occurred with (±)-Amiflamine in both tissues.Kinetic investigations using homogenates from pretreated rats showed (±)-Amiflamine to be a competitive inhibitor;cimoxatone was competitive in the liver but showed a more complex pattern in the brain.Moclobemide was noncompetitive in both tissues, as has been shown previously for brofaremine.Moclobemide prevented the deamination of dopamine and serotonin released from their striatal stores by tetrabenazine nearly as efficiently as clorgyline at an otherwise equieffective dose;cimoxatone was somewhat less effective relative to the reference compound, as was brofaremine, which was however given at a more effective dose.(±)-Amiflamine was much less effective than clorgyline at protecting dopamine, but equieffective with respect to serotonin[1]. |
| In vivo | (±)-Amiflamine was 3 times less potent within noradrenergic neurons than within serotonergic neurons. A brain to plasma ratio of about 20:1 was found for (±)-Amiflamine and its metabolites. The plasma and the brain concentrations of the N-demethylated metabolite [FLA 788(+)] exceeded that of (±)-Amiflamine after a single dose, whereas the N,N-demethylated [FLA 668(+)] was found in low concentrations. The effect on MAO-A correlated significantly with the plasma and the brain concentration of FLA 788(+)[2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 32.5 mg/mL (169 mM)
|
| Keywords | Monoamine Oxidase | MAO | Inhibitor | inhibit | FLA-336 | FLA336 | FLA 336 | (±)-Amiflamine | (±)Amiflamine | (±) Amiflamine |
| Inhibitors Related | Hydroxyamine hydrochloride | Hydralazine hydrochloride | Rosmarinic acid | Safinamide | Azure B | 1,4-Naphthoquinone | Paeonol | Isatin | Methylene Blue | Methylene Blue trihydrate | Furazolidone | Allylthiourea |
| Related Compound Libraries | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Antidepressant Compound Library | Neuronal Signaling Compound Library | Inhibitor Library | Mitochondria-Targeted Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Metabolism Disease Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:5728-52-9
$42.00 / 500mg
-
CAS:666261-80-9
$30.00 / 1mg
-
CAS:2541792-70-3
$68.00 / 1mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$1520.00/25mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-28 |
United States